Ocular Therapeutix Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones Dextenza Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over

Ocular Therapeutix Provides 2022 Year

End Corporate Update and Reviews Expected 2023 Milestones

Dextenza Net Product Revenue in the Fourth

Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter

Dextenza Net Product Revenue for the Year Ending

2022 is Estimated to be $50.2 million, Representing Growth of Approximately 20% Over Prior Year

10-month Interim Data from the U.S.-based Phase

1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented at the Upcoming Angiogenesis

Conference in February 2023

Phase 1 Clinical Trial of OTX-TKI (axitinib

intravitreal implant) for the Treatment of Diabetic Retinopathy Initiated in December 2022

Top-Line Data from Phase 2 Clinical Trial of

OTX-TIC (travoprost intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected

Mass.-(BUSINESS WIRE)- January 6, 2023 - Ocular Therapeutix, Inc. (NASDAQ:OCUL),

a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions

of the eye, today provided a corporate update on the progress of its key programs.

"2022 marked a year in which Ocular made good progress against

its corporate mission of becoming a mid-tier strategic within ophthalmology", said Antony Mattessich, President and CEO. "DEXTENZA,

despite challenging market conditions, has established itself as a material and important product and demonstrated renewed growth in the

fourth quarter of 2022."

Mr. Mattessich continued: "The

highlight of our year at Ocular was further development within our pipeline. At AAO in September, we presented impressive interim 6- and

7-month data from our US-based Phase 1 clinical trial of OTX-TKI for the treatment of wet AMD. We believe the data further strengthen

our ongoing development in wet AMD and supports proof of concept for OTX-TKI's potential in the treatment of VEGF-mediated vascular

retinal diseases, including diabetic retinopathy. Both wet AMD and diabetic retinopathy represent large markets where durability could

significantly reduce the burden of anti-VEGF injections and improve real-world outcomes for patients. With that in mind, we initiated

a Phase 1 clinical trial in diabetic retinopathy in December 2022 and anticipate presenting interim data from this trial in 2023.

We also plan to report 9- and 10-month data from the U.S. Phase 1 trial of OTX-TKI in wet AMD at the Angiogenesis meeting in February 2023.

Lastly, we plan to present much anticipated data from our Phase 2 clinical trial of OTX-TIC for the treatment of glaucoma in Q4 2023.

Overall, executing efficiently and working within the constraints of existing resources, we believe that the Company can pull forward

our core development programs to be Phase 3-ready."

DEXTENZA (dexamethasone ophthalmic

insert) 0.4mg is FDA approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated

with allergic conjunctivitis.

OTX-TKI (axitinib intravitreal

implant) for the potential treatment of wet AMD and other retinal vascular diseases.

OTX-TKI (axitinib intravitreal implant) for the potential

treatment of Diabetic Retinopathy (DR)

OTX-TIC (travoprost intracameral implant)

for the treatment of patients with primary open-angle glaucoma or ocular hypertension.

OTX-DED (dexamethasone intracanalicular

insert) for the short-term treatment of the signs and symptoms of dry eye disease and OTX-CSI (cyclosporine intracanalicular insert) for

the chronic treatment of dry eye disease

2022 Preliminary Results

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused

on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary

bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA ,

is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated

with allergic conjunctivitis. Ocular Therapeutix's earlier stage development assets include: OTX-TKI (axitinib intravitreal implant),

currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral implant),

currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine

intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term

treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.

DEXTENZA is FDA approved for the treatment

of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. DEXTENZA is a

corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid, and into the

canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. DEXTENZA resorbs and

exits the nasolacrimal system without the need for removal.

Please see full Prescribing and Safety Information at www.DEXTENZA.com.

Forward Looking Statements

Any statements in this press release about

future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA , ReSure Sealant, or any

of the Company's product candidates; the development and regulatory status of the Company's product candidates, such as the

Company's development of and prospects for approvability of OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension,

OTX-TKI for the treatment of retinal diseases including wet AMD and diabetic retinopathy, OTX-DED for the short-term treatment of the

signs and symptoms of dry eye disease, and OTX-CSI for the chronic treatment of dry eye disease; the Company's plans to advance

the development of its product candidates or preclinical programs; the potential utility of any of the Company's product candidates;

the size of potential markets for the Company's product candidates; the potential benefits and future operations of Company collaborations,

including any potential future costs or payments thereunder; estimated 2022 financial results, including estimated net product revenue

and cash and cash equivalents; the sufficiency of the Company's cash resources and other statements containing the words "anticipate,"

"believe," "estimate," "expect," "intend", "goal," "may", "might,"

"plan," "predict," "project," "target," "potential," "will," "would,"

"could," "should," "continue," and similar expressions, constitute forward-looking statements within the

meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking

statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that

could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly

from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and

costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct

of post-approval studies, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives

regulatory approval, the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA,

the initiation, timing, conduct and outcomes of clinical trials, whether clinical trial data such as the data reported in this release

will be indicative of the results of subsequent clinical trials in the same or other indications or that interim data will be indicative

of the full data from a clinical trial, uncertainties as to the timing and availability of data from clinical trials and expectations

for regulatory submissions and approvals, the Company's ability to enter into and perform its obligations under collaborations and

the performance of its collaborators under such collaborations, the Company's scientific approach and general development progress,

the availability or commercial potential of the Company's product candidates, the Company's ability to meet supply demands,

uncertainties as to the Company's preliminary financial results for Q4 2022 and 2022, which are estimates based on preliminary and

unaudited information, subject to the completion of financial closing procedures and have not been audited or reviewed by the Company's

independent public accounting firm, the Company's ability to generate its projected net product revenue and in-market sales on the

timeline expected, if at all, the sufficiency of cash resources, the Company's existing indebtedness, the ability of the Company's

creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration

of the COVID-19 pandemic including its effect on the Company's revenues and relevant regulatory authorities' operations, any

additional financing needs, the Company's ability to recruit and retain key personnel, and other factors discussed in the "Risk

Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission.

In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this

press release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However,

while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims

any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking

statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.